A phase i trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy

Ramesh K. Ramanathan, Joe J. Stephenson, Glen J. Weiss, Linda A. Pestano, Ann Lowe, Alton Hiscox, Rafael A. Leos, Julie C. Martin, Lynn Kirkpatrick, Donald A. Richards

Research output: Contribution to journalArticlepeer-review

23 Scopus citations

Fingerprint Dive into the research topics of 'A phase i trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapy'. Together they form a unique fingerprint.

Medicine & Life Sciences